Wedbush Comments on Immunome’s Q1 Earnings (NASDAQ:IMNM)

Immunome, Inc. (NASDAQ:IMNM) – Wedbush lifted their Q1 2025 EPS estimates for shares of Immunome in a report issued on Wednesday, March 19th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.51) per share for the quarter, up from their prior estimate of ($0.72). Wedbush currently has a “Outperform” rating and a $33.00 target price on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Wedbush also issued estimates for Immunome’s Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.86) EPS, FY2026 earnings at ($1.80) EPS and FY2027 earnings at ($1.35) EPS.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The firm had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million.

Several other brokerages have also commented on IMNM. Guggenheim lowered their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Lifesci Capital assumed coverage on shares of Immunome in a research report on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target for the company. Finally, Stephens reissued an “overweight” rating and set a $30.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $25.50.

Immunome Stock Down 0.4 %

IMNM opened at $8.15 on Monday. Immunome has a 52 week low of $8.12 and a 52 week high of $26.70. The stock has a market cap of $650.18 million, a PE ratio of -1.00 and a beta of 1.93. The business has a 50 day moving average of $9.72 and a 200-day moving average of $11.49.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall acquired 150,000 shares of Immunome stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Immunome

A number of institutional investors have recently made changes to their positions in IMNM. Charles Schwab Investment Management Inc. raised its holdings in Immunome by 217.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after acquiring an additional 302,916 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after purchasing an additional 144,557 shares during the last quarter. Magnus Financial Group LLC raised its stake in shares of Immunome by 107.8% in the fourth quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock worth $569,000 after purchasing an additional 27,777 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock valued at $6,881,000 after purchasing an additional 85,580 shares in the last quarter. Finally, Barclays PLC boosted its position in shares of Immunome by 125.9% during the third quarter. Barclays PLC now owns 105,886 shares of the company’s stock valued at $1,547,000 after buying an additional 59,016 shares during the last quarter. Hedge funds and other institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.